TITLE

COMPUGEN ACHIEVES MILESTONE IN COLLABORATION

PUB. DATE
August 2014
SOURCE
Biotech Business;Aug2014, Vol. 27 Issue 8, p1
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article reports the achievement of Compugen Ltd., a drug discovery company, in the cancer immunotherapy collaboration with the firm Bayer Healthcare. Topics discussed include focus of the collaboration on the development and commercialization of therapeutic antibodies against two immune checkpoint regulators found by Compugen, views of Anat Cohen Dayag, president of Compugen, and Bayer's commercialization rights for potential cancer therapeutics.
ACCESSION #
97380416

 

Related Articles

  • Compugen Rockets on $540M Bayer Immunotherapy Alliance. Boggs, Jennifer // BioWorld International;8/7/2013, Vol. 18 Issue 32, p1 

    The article reports on the 44.5 percent increase in the share price of Compugen Ltd., a drug discovery company, following news of a possible 540-million-dollar deal with pharmaceutical company Bayer Healthcare to develop cancer immunotherapy drugs. Compugen began operating in the 1990s as a...

  • For Treatment of Hepatocellular Carcinoma, at Least Half of Surveyed Oncologists View a Four-Month Improvement in Overall Survival or in Progression-Free.  // Biomedical Market Newsletter;6/30/2012, Vol. 21, p1 

    The article presents information on a survey conducted by Decision Resources Inc. for the oncologists in the U.S. As per the survey it was found that majority of the oncologists prefer to use Nexavar from Bayer Healthcare AG as a treatment for advanced hepatocellular carcinoma (HCC) patients. It...

  • BROKEN SCIENCE. Bailey, Ronald // Reason;Feb2016, Vol. 47 Issue 9, p18 

    The article talks about the science crisis and the reliability of the published research findings related to biomedicine, genetics and epidemiology. It states that researchers at Bayer Healthcare reported that they could not replicate preclinical studies for developing cancer and cardiovascular...

  • Unique cancer therapy form Indian sought by other nations.  // Asian Pacific Post;3/18/2010, p5 

    The article reports on a new cancer treatment developed by the Institute of Cellular Therapies (ICT) in India that uses cell-based cancer immunotherapy.

  • Ardea Licenses MEK Inhibitors to Bayer in Deal Valued at $407M. Hollingsworth, Catherine // BioWorld Today;4/29/2009, Vol. 20 Issue 81, p1 

    The article reports on the licensing agreement between Ardea Biosciences Inc. and Bayer Healthcare AG. Under the agreement, Bayer will create potential treatments for cancer using mitogen-activated protein kinase/extracellular signal-regulated kinase (MEK) inhibitor from Ardea. The deal costs up...

  • Bayer Expands Research in Cancer Immunotherapy with Compugen Pact. Cartwright, Heather // PharmaDeals Review;2013, Vol. 2013 Issue 8, p82 

    Bayer has furthered its research focus on cancer immunotherapy by forming a collaboration with Israeli biotech Compugen, which specialises in computational approaches for drug discovery. The deal will centre on advancing antibody-based therapeutics against two novel immune checkpoint regulators...

  • Immunotherapies shift research focus from tumor to technique. Todak, Alexandra // Hem/Onc Today;5/25/2014, Vol. 15 Issue 10, p1 

    The article focuses on the influence of immunotherapy on the paradigm for cancer treatment and the need for more research on how immunotherapies can complement each other and presents insights from immuno-oncologists.

  • FDA/EMA ROUNDUP.  // MondayMorning;3/4/2013, Vol. 21 Issue 8, p1 

    The article offers news briefs related to pharmaceutical industries as of March 2013. The U.S. Food and Drug Administration (FDA) has approved Bayer Healthcare regarding its cancer pill for treating intestinal tract tumors. FDA has approved Osaka, Japan-based Shionogi & Co. Ltd. regarding the...

  • Product Briefs.  // Biomedical Business & Technology;Mar2009, Vol. 32 Issue 3, p28 

    The article focuses on the discovery and verification by Compugen of CGEN-327, a molecular biomarker candidate for the diagnosis of ovarian cancer. It is reportedly a previously unknown variant of the Human Epididymis Protein 4 gene, a known biomarker for the cancer. The company's pursuit of a...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics